Liquid Biopsy Biomarkers for Aggressive Prostate Cancer Discovered
By LabMedica International staff writers Posted on 05 Jul 2016 |
Using targeted proteomics on noninvasive liquid biopsies, researchers have discovered biomarkers that provide signatures of aggressive (extracapsular) prostate cancer (PC), which could enable diagnosis before treatment and so help many low-risk PC patients avoid surgery.
Currently, needle biopsies are used to help diagnose PC, but this technique may not detect hidden tumors or cancer that has already spread beyond the organ. The new research advances the quest to develop a precise, noninvasive diagnostic tool that can address over-treatment of slow-growing, low-risk PC.
"We believe we have found a better way that allows us to predict which patients have a slow-growing versus aggressive PC using non-invasive biomarkers. This could eventually help us personalize cancer treatment for these patients," said principal investigator Prof. Dr. Thomas Kislinger, of Princess Margaret Cancer Centre, University Health Network (UHN; Toronto, Canada), and of University of Toronto.
"A fluid-based biomarker would be ideal … to spare patients with indolent (slow-growing) disease from unnecessary procedures, while identifying and treating those who would benefit from treatment intensification," said co-lead author Dr. Yunee Kim.
The Kislinger team – in collaboration with Paul Boutros, Ontario Institute for Cancer Research (Canada), and O. John Semmes, Eastern Virginia Medical School (Norfolk, VA, USA) – used urine samples containing prostatic secretions from 210 patients after they had undergone digital rectal examinations (DRE, the standard clinical "first step" to determine need for further diagnostic testing of the prostate). The research took four years and involved samples from almost 300 patients.
"We used targeted proteomics to accurately quantify hundreds of proteins in urine samples (post-DRE) to identify liquid biopsy signatures. The first round of research involved 80 patients and quantified 150 proteins that were then narrowed down to 34 for further investigation. The next round involved a second, independent cohort of 210 patients,” said Dr. Kislinger, "Applying computational biology, we used the quantitative data from mass spectrometry to develop the fluid biomarkers for aggressive PC." He added, "The next step will be further studies with urine samples from 1,000 international patients to validate if the biomarkers identified have broader clinical utilities in PC."
The study, by Kim Y, Jeon J, et al, was published online ahead of print June 28, 2016, in the journal Nature Communications.
Related Links:
University Health Network
Currently, needle biopsies are used to help diagnose PC, but this technique may not detect hidden tumors or cancer that has already spread beyond the organ. The new research advances the quest to develop a precise, noninvasive diagnostic tool that can address over-treatment of slow-growing, low-risk PC.
"We believe we have found a better way that allows us to predict which patients have a slow-growing versus aggressive PC using non-invasive biomarkers. This could eventually help us personalize cancer treatment for these patients," said principal investigator Prof. Dr. Thomas Kislinger, of Princess Margaret Cancer Centre, University Health Network (UHN; Toronto, Canada), and of University of Toronto.
"A fluid-based biomarker would be ideal … to spare patients with indolent (slow-growing) disease from unnecessary procedures, while identifying and treating those who would benefit from treatment intensification," said co-lead author Dr. Yunee Kim.
The Kislinger team – in collaboration with Paul Boutros, Ontario Institute for Cancer Research (Canada), and O. John Semmes, Eastern Virginia Medical School (Norfolk, VA, USA) – used urine samples containing prostatic secretions from 210 patients after they had undergone digital rectal examinations (DRE, the standard clinical "first step" to determine need for further diagnostic testing of the prostate). The research took four years and involved samples from almost 300 patients.
"We used targeted proteomics to accurately quantify hundreds of proteins in urine samples (post-DRE) to identify liquid biopsy signatures. The first round of research involved 80 patients and quantified 150 proteins that were then narrowed down to 34 for further investigation. The next round involved a second, independent cohort of 210 patients,” said Dr. Kislinger, "Applying computational biology, we used the quantitative data from mass spectrometry to develop the fluid biomarkers for aggressive PC." He added, "The next step will be further studies with urine samples from 1,000 international patients to validate if the biomarkers identified have broader clinical utilities in PC."
The study, by Kim Y, Jeon J, et al, was published online ahead of print June 28, 2016, in the journal Nature Communications.
Related Links:
University Health Network
Latest Molecular Diagnostics News
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis